| Ytd | 37.82% | |
| 1y | -20.53% |
| Open | 12.50 | Prev Close | 12.14 | Low | 12.18 | High | 12.65 | Mkt Cap | 1.73B |
| Vol | 960.89K | Avg Vol | 4.03M | EPS | -3.34 | P/E | N/A | Forward P/E | -4.67 |
| Beta | 1.82 | Short Ratio | 12.86 | Inst. Own | 99.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 12.02 | 200-d Avg | 12.71 | 1yr Est | 24.00 |
NTLA News
Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditar
NTLA wins FDA priority review for lonvo-z, with a March 10, 2027 decision, potentially adding its fi
Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) shares passed below its fifty day movin
Intellia Therapeutics, Inc. (NTLA) Presents at Morgan Stanley 24th Annual Global Healthcare Conferen
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outp
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral a
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA)
Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutio
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolution
Cathie Wood's ARK sold 40,392 Shopify shares after a 25% August rally. Here's what ARKK and
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outp
Evercore ISI Group analyst Jonathan Miller upgrades Intellia Therapeutics (NASDAQ:NTLA) from In-L
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.80) per share which missed the
Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pha
Wolfe Research analyst Andy Chen downgrades Intellia Therapeutics (NASDAQ:NTLA) from Peer Perform
Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral a
Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar
U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% a
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outp
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral
Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA)
Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European A
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolution
Intellia will also have a poster presentation detailing the burdens experienced by HAE patients livi
Bernstein analyst William Pickering maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market P
Top Wall Street analysts updated their ratings on top companies. For full list of changes, including
U.S. stock futures up, Nasdaq 100 gains 100 points. Robinhood shares fall 10.7% after reporting lowe
Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the compan
Top analysts upgraded RPM, Dow, Intellia, Sempra, & Target stocks. See ratings & targets. Po
Benzinga's top Wall Street analysts changed outlook on these names: AVAV cut to $290, OCUL raise
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil
